Glioblastoma Multiforme, Glioma, Neuroectodermal Tumors
Conditions
Keywords
Tissue Bank, Glioblastoma Multiforme, NAT2, EGFR, MGMT, Brain and Spinal TumorGliomas
Brief summary
The purpose of this study is to establish a Brain and Spinal Tumor Tissue/Specimen repository to serve as a resource for current and future scientific studies.
Detailed description
Glioblastoma multiforme (GBM) is the most common and lethal primary Brain and Spinal Tumor in adults. It is nearly uniformly fatal, with a median survival of approximately one year, despite modern treatment modalities. Efforts to understand why some patients live longer or shorter than the average may provide insights into the biology of these neoplasms. For years, researchers have tried to identify independent predictors that could help in treatment planning. With the recent interest in molecular biology and molecular genetics, tumor markers are now being examined as potential predictors. A marker that could predict tumor response to therapy, the likelihood of recurrence, and survival would thus be quite useful.
Interventions
None listed
Sponsors
Taipei Medical University WanFang Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a suspected or confirmed diagnosis of Brain and Spinal Tumor * Age greater than 20 * Signed consent
Exclusion criteria
* Known HIV infection * Any other clinical condition which, in the opinion of the principal investigator, would not allow completion of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collect, annotate, and store fresh frozen specimens of normal tissue, tumors, and pre-malignant lesions for biological investigation. | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Establish a database to link materials acquisition, pathologic, and clinical information on patients who participate in the protocol | 5 years |
| To utilize the clinical database to perform clinical and pathological correlation with the results of current and future scientific studies | 5 years |
| To evaluate various NAT2, EGFR and MGMT for evidence of genomic and biochemical activation | 5 years |
| Collect, process, and store serum, plasma and isolate lymphocytes from blood drawn from patients with Brain and Spinal Tumor | 5 years |
| To correlate tumor genotype and signaling abnormalities with clinical response to NAT2, EGFR, MGMT and/or other potential molecular targets inhibitors | 5 years |
| Analysis of laboratory findings in relationship to patient demographics and clinical course | 5 years |
| To test the effect of small molecule inhibitors on the activation of wild-type and mutant NAT2, EGFR, MGMT and/or other potential molecular targets | 5 years |
Countries
Taiwan
Contacts
Primary ContactKuo-Sheng Hung, M.D., Ph. D.
Outcome results
None listed